A Phase II Add-on Study of Vorinostat (VOR) in Higher Risk Myelodysplastic Syndrome with Failure of Hypomethylating Agents (HMA): The GFM Azavor Study

被引：0

作者：

Prebet, Thomas ^{[1
,2
]}

Delaunay, Jacques ^{[3
]}

Wattel, Eric ^{[4
]}

Braun, Thorsten ^{[5
]}

Cony-Makhoul, Pascale ^{[6
]}

Dimicoli, Sophie ^{[7
]}

Wickenhauser, Stefan ^{[8
]}

Lejeune, Julie ^{[9
]}

Chevret, Sylvie ^{[10
]}

Chermat, Fatiha ^{[11
]}

Fenaux, Pierre ^{[2
,12
,13
]}

Vey, Norbert ^{[14
]}

机构：

[1] Yale Univ, Sch Med, Dept Internal Med, Sect Hematol, New Haven, CT 06510 USA

[2] Grp Francophone Myelodysplasies, Paris, France

[3] Nantes Univ Hosp, Dept Hematol, Nantes, France

[4] Univ Lyon 1, F-69365 Lyon, France

[5] CHU Avicenne, Hematol Clin, Bobigny, France

[6] Ctr Hosp Annecy Genevois, Dept Hematol, Metz, France

[7] CHU Bordeaux, Serv Hematol, Pessac, France

[8] CH Nimes, Nimes, France

[9] Hop St Louis, AP HP, Paris, France

[10] Stat St Louis Hosp, Paris, France

[11] Hop St Louis, GFM, Paris, France

[12] Univ Paris 07, Hop St Louis, Serv Hematol Seniors, Paris, France

[13] Univ Paris 08, Hop Avicenne, Serv Hematol Clin, Bobigny, France

[14] Inst J Paoli I Calmettes, Hematol, F-13009 Marseille, France

来源：

BLOOD | 2015年 / 126卷 / 23期

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：3

共 50 条

[1] A Phase I-II Study of Vorinostat and Low Dose Cytarabine for Patients Treated for High Risk Myelodysplastic with Azacytidine Failure: The GFM-VOR2007 Study.
Prebet, Thomas
Braun, Thorsten
Rauzy, Odile Beyne
Dreyfus, Francois
Stamatoullas, Aspasia
Wattel, Eric
Ame, Shanti
Raffoux, Emmanuel
Delaunay, Jacques
Salanoubat, Celia
Mathieu, Isabelle
Chermat, Fatiha
Ades, Lionel
Fenaux, Pierre
Vey, Norbert
BLOOD, 2010, 116 (21) : 1632 - 1632
[2] A phase II study of omacetaxine mepesuccinate for patients with higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia after failure of hypomethylating agents
Short, Nicholas J.
Jabbour, Elias
Naqvi, Kiran
Patel, Ami
Ning, Jing
Sasaki, Koji
Nogueras-Gonzalez, Graciela M.
Bose, Prithviraj
Kornblau, Steven M.
Takahashi, Koichi
Andreeff, Michael
Sanchez-Petitto, Gabriela
Estrov, Zeev
Dinardo, Courtney D.
Montalban-Bravo, Guillermo
Konopleva, Marina
Alvarado, Yesid
Bhalla, Kapil N.
Fiskus, Warren
Khouri, Maria
Islam, Rubiul
Kantarjian, Hagop
Garcia-Manero, Guillermo
AMERICAN JOURNAL OF HEMATOLOGY, 2019, 94 (01) : 74 - 79
[3] Addition of suberoylanilide hydroxamic acid (Vorinostat) to azacitidine for patients with higher risk myelodysplastic syndromes and azacitidine failure: a phase II add-on study from the Groupe Francophone des Myelodysplasies
Prebet, Thomas
Delaunay, Jacques
Wattel, Eric
Braun, Thorsten
Cony-Makhoul, Pascale
Dimicoli, Sophie
Wickenhauser, Stephan
Lejeune, Julie
Chevret, Sylvie
Chermat, Fatiha
Fenaux, Pierre
Vey, Norbert
BRITISH JOURNAL OF HAEMATOLOGY, 2018, 180 (05) : 735 - 737
[4] Final Results from a Phase II Study Combining Azacitidine and Pembrolizumab in Patients with Higher-Risk Myelodysplastic Syndrome after Failure of Hypomethylating Agent Therapy
Chien, Kelly S.
Borthakur, Gautam
Naqvi, Kiran
Daver, Naval
Bravo, Guillermo Montalban
Cortes, Jorge E.
DiNardo, Courtney D.
Jabbour, Elias
Alvarado, Yesid
Andreeff, Michael
Bose, Prithviraj
Jain, Nitin
Sheppard, Kimberly
Klingner-Winton, Cheri
Pierce, Sherry A.
Dong, Xiao Qin
Soltysiak, Kelly A.
Kantarjian, Hagop M.
Garcia-Manero, Guillermo
BLOOD, 2020, 136
[5] Addition of the SMO Inhibitor Sonidegib to Azacitidine in Patients with Higher Risk Myelodysplastic Syndrome (MDS) Who Failed to Respond or Lost Response to AZA Alone: Results of a Phase 1-2 Add-on Study By the GFM
Vey, Norbert
BLOOD, 2018, 132
[6] A Phase Ib/II Study Evaluating Navitoclax after Failure of Hypomethylating Agent and Venetoclax for Treatment of Relapsed or Refractory High-Risk Myelodysplastic Syndrome
Keiffer, Gina
Meyer, Sara E.
Eischen, Christine
Outschoorn, Ubaldo Martinez
Alpdogan, Onder
Binder, Adam F.
Porcu, Pierluigi
Wilde, Lindsay
Kasner, Margaret
Palmisiano, Neil
BLOOD, 2023, 142
[7] A Phase I/II Study of Combination of Azacitidine, Venetoclax and Pevonedistat in Patients with Newly-Diagnosed Secondary Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) with Hypomethylating Agent (HMA) Failure
Ong, Faustine
Garcia-Manero, Guillermo
Montalban-Bravo, Guillermo
Alvarado, Yesid
Ohanian, Maro
Konopleva, Marina
Jabbour, Elias
Jain, Nitin
Borthakur, Gautam
DiNardo, Courtney D.
Daver, Naval
Issa, Ghayas C.
Sasaki, Koji
Chien, Kelly S.
Takahashi, Koichi
Andreeff, Michael
Muftuoglu, Muharrem
Delumpa, Ricardo
Mayor, Ejiroghene
Loiselle, Christopher
Waller, Lourdes
Banks, Glenda
Kantarjian, Hagop
Cortes, Jorge E.
Short, Nicholas
BLOOD, 2022, 140 : 6206 - 6208
[8] A PHASE II STUDY OF THE EFFICACY AND SAFETY OF AN INTENSIFIED SCHEDULE OF AZACITIDINE IN HIGHER RISK MDS PATIENTS: A STUDY BY THE GFM
Ades, L.
Guerci-Bresler, A.
Makhoul, P. Cony
Legros, L.
Delaunay, J.
Recher, C.
Sebert, M.
Lejeune, J.
Chevret, S.
Fenaux, P.
LEUKEMIA RESEARCH, 2015, 39 : S44 - S44
[9] Phase 2 Study of Low-Dose Clofarabine Plus Cytarabine for Patients With Higher-Risk Myelodysplastic Syndrome Who Have Relapsed or Are Refractory to Hypomethylating Agents
Jabbour, Elias
Faderl, Stefan
Sasaki, Koji
Kadia, Tapan
Daver, Naval
Pemmaraju, Naveen
Patel, Keyur
Khoury, Joseph D.
Bueso-Ramos, Carlos
Bohannan, Zachary
Ravandi, Farhad
Borthakur, Gautam
Verstovsek, Srdan
Miller, Darla
Maduike, Rita
Hosing, Chitra
Kantarjian, Hagop M.
Garcia-Manero, Guillermo
CANCER, 2017, 123 (04) : 629 - 637
[10] Phase I/II Combination Study of Azacitidine and Venetoclax Post Hypomethylating Agents Failure in High Risk MDS and CMML
Braish, Julie
Montalban-Bravo, Guillermo
Ravandi, Farhad
Short, Nicholas J.
Kadia, Tapan M.
Ohanian, Maro
Chien, Kelly S.
Masarova, Lucia
Sasaki, Koji
Yilmaz, Musa
Daver, Naval
Borthakur, Gautam
Kantarjian, Hagop M.
Garcia-Manero, Guillermo
BLOOD, 2024, 144 : 3209 - 3210

← 1 2 3 4 5 →